Company Will Host Conference Call at 5:00 p.m. (ET) on Monday, April 8, 2019 Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today...
First Clinical Trial to Evaluate the Potential of the Personal Neoantigen Vaccine NEO-PV-01 in Combination with Standard of Care in First-Line Metastatic NSCLC Treatment Setting Neon Therapeutics, Inc. (Nasdaq: NTGN), a clinical-stage immuno-oncology company...
All Primary Efficacy and Safety Endpoints, and Key Secondary Endpoints Achieved Profound Medical Corp. (TSX:PRN; OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which combine real-time Magnetic Resonance...
The National Cancer Institute’s (NCI) National Clinical Trials Network (NCTN) recently designated the MCW Cancer Center as a Lead Academic Participating Site (LAPS) for the strength and innovation of its ongoing research and science and robust participation in...
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, has expanded two additional cohorts from the Phase II SUMMIT clinical trial investigating its lead drug candidate neratinib in patients with solid tumors who have an activating EGFR or HER2...
Company Announced IND Clearance Today for Phase 1/2 Clinical Trial Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today preclinical data demonstrating that HMI-102, its gene therapy candidate for the treatment of phenylketonuria (PKU),...
Email
Text